Tissue Regenix Ltd

Tissue Regenix Ltd

Tissue Regenix Group is a medical technology company focused on regenerative medicine products. It was founded to commercialize tissue engineering technologies and is headquartered in Leeds, UK with a second facility in San Antonio, Texas. The company’s two platform technologies are dCELL for soft tissue decellularization and BioRinse for sterile bone allografts. Flagship products include DermaPure (soft tissue matrix), ConCelltrate (bone graft), OrthoPure XT (ligament reconstruction implant, not available in the US), and AmnioWorks (birth tissue products). Applications span BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology, and Cardiac. Tissue Regenix operates two facilities: the Leeds site houses corporate offices and manufactures porcine medical devices under ISO 13485:2016, and the San Antonio site processes, stores, and distributes human tissues (HCT/P) in compliance with FDA, AATB, and state standards. The Leeds facility also serves as an R&D hub with connections to the University of Leeds. No team size or AUM data is publicly available. A structural differentiator is the company’s dual-platform approach — combining decellularized soft tissue (dCELL) and sterile bone allograft (BioRinse) processing under one organization, with both human-donor and animal-derived products, enabling broad surgical coverage.